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Spinal cord ischemia (SCI) is clearly one of the more devastat-
ing complications after the repair of any thoracic pathology by any
means. The multifactorial etiology of the complication has so far
resulted in a variety of management strategies that have failed to
garner uniform adoption. Endografting of thoracic aneurysms
(TEVAR) was greeted with the expectation that this feared out-
come would be diminished by avoiding aortic clamping and pro-
longed ischemia of the cord. This optimism appears well justified
by most early published results, as SCI seems to occur in 5% of
cases and mostly in aneurysmal pathology of the thoracic aorta and
less so with dissection or transection.1-4
In an effort to further limit the occurrence of SCI, a diligent
search for predisposing risk factors has so far resulted in a myriad of
associations with little consensus about the relative importance of
any. Notable suspects include length of thoracic aortic coverage,
left subclavian artery exclusion without reconstruction, elimination
of intercostal blood supply, especially the artery of Adamkiewicz,
poor lumbar and internal iliac artery collaterals, intraoperative
hypotension, conduit use for access, and underlying aneurysmal
pathology. The presence of a concurrent or remotely repaired
abdominal aortic aneurysm (AAA) has also been repeatedly impli-
cated, with only sparse supporting evidence.
This issue of the Journal of Vascular Surgery brings the reader
two reports focusing on the risk of SCI after TEVAR in patients
with AAA. The reports differ in methodology, results, patient
population, and extent of use of prophylactic spinal drainage, yet
are remarkably similar in the estimated risk of SCI in patients with
prior AAA repair: 12.5% in a multicenter study limited to thoracic
aneurysms and 14% in a single-center series with a potpourri of
diagnoses. The incidence is notably the same as that reported in a
smaller series by Baril in 2006.5
Despite the inherent methodologic problems of all these
retrospective analyses, and other negative reports, the evidence is
mounting that SCI risk is elevated after TEVAR in patients with
remote aneurysm repair. The incidence of SCI seems to be signif-
icantly higher in this patient subgroup irrespective of other risk
factors that may exist. The SCI hazard ratio in patients with AAA
seems to range between 4 and 7.
The report from the University of Florida by Martin indicatesuntreated concurrent AAA as small as 3.0 cm in diameter, a size
rarely considered an aneurysm in most clinical settings. This find-
ing adds another dimension to the association of SCI with any
current aneurysmal pathology of the abdominal aorta and clearly
constitutes a cause for concern in the preoperative risk benefit
assessment before TEVAR.
The rest of the information provided by these two studies is
somewhat disparate due to different methodology and inclusion
criteria. The multicenter study by Schlosser reports a somewhat
enviable SCI rate of only 1.7% after TEVAR for thoracic aneurysms
in the absence of prior AAA repair. In the absence of any abdominal
aortic pathology, Martin still reports a rate of 5.6% in a more
diverse group including patients with dissections, transections, and
other pathologies that would have been expected to lower the
incidence of this complication.
An SCI rate of 10% in the entire TEVAR series from a
group with a large experience such as the University of Florida
is quite sobering, pointing out that we have a long way to go
before understanding all the factors that may influence the
development of this debilitating complication. The contribu-
tions of emergency interventions as well as hybrid procedures to
this elevated risk is not entirely clear from the data presented.
Prospective focused collection of data may be required before
providing guidelines for the proper selection of patients and con-
duct of the operation to minimize these unfortunate outcomes.
In the meantime these two studies provide a strong reminder
that caution should be exercised when offering TEVAR to a large
group of patients who present with remote or concurrent AAA. A
careful analysis of the risk/benefit ratio under these circumstances
should lead us to only offer TEVAR to patients with a higher risk
profile of the underlying pathology, raising the size threshold for
intervention on aneurysmal disease of the thoracic aorta.
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